PrEP and post-exposure prophylaxis during COVID-19

PrEP and post-exposure prophylaxis (PEPSE and PEP) will continue to be available during the COVID-19 pandemic, but there will be changes to service delivery and to the PrEP Impact Trial.

The Association of Directors of Public Health (ADPH) recommends that assessment of PEPSE, PEP, and PrEP should be provided remotely with postal issuing of drugs.

PrEP routine commissioning will be taking a phased approach by local authorities in 2020/21 due to COVID-19 pressures, the ADPH says. However, clinics participating in the PrEP Impact Trial should continue to review and supply to registered patients.

The PrEP Impact Trial team has issued information on the running of the trial during the COVID-19 restrictions.

• The trial will remain open but recruitment is likely to be paused.
• Follow-up visits will be decided based on local circumstances; some changes have been made to the trial to make this easier for services, and for participants to continue to access PrEP where possible and if still required.
• ​The page also provides information for trial participants and others who wish to access PrEP during the pandemic.